Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: Focus on olmesartan medoxomil

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 405-416

  Mason, R Preston ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

Author keywords

Angiotensin II receptor blocker; Antihypertensive; Atherosclerotic process; Cardiovascular outcomes; Coronary artery disease; Olmesartan medoxomil; RAAS suppression

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AUTACOID; IMIDAZOLE DERIVATIVE; NITRIC OXIDE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; HYPERTENSION; METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; HUMANS; HYPERTENSION; IMIDAZOLES; INFLAMMATION MEDIATORS; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME;

EID: 83755179668     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S20737     Document Type: Review

References (77)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
2. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
3. Scott J. The pathogenesis of atherosclerosis and new opportunities for treatment and prevention. J Neural Transm Suppl. 2002;(63):1-17.
4. Wasserman BA. Clinical carotid atherosclerosis. Neuroimaging Clin N Am. 2002;12(3):403-419.
5. Li JJ, Chen JL. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses. 2005;64(5):925-929.
6. Rosenfeld ME. An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis. Z Kardiol. 2000;89(Suppl 7):2-6.
7. Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Relationship between aortic calcification and atherosclerotic disease in patients with abdominal aortic aneurysm. Int Angiol. 2000;19(3):276-279.
8. Kramer CM, Anderson JD. MRI of atherosclerosis: diagnosis and monitoring therapy. Expert Rev Cardiovasc Ther. 2007;5(1): 69-80.
9. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(2):233-246.
10. Standridge JB. Hypertension and atherosclerosis: clinical implications from the ALLHAT trial. Curr Atheroscler Rep. 2005;7(2): 132-139.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
12. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244-1263.
13. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7-17.
14. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96(12):4219-4225.
15. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121-128.
16. Gronholdt ML, Dalager-Pedersen S, Falk E. Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J. 1998;19(Suppl C): C24-C29.
17. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27(1):15-26.
18. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000; 247(3):349-358.
19. Sakariassen KS, Barstad RM. Mechanisms of thromboembolism at arterial plaques. Blood Coagul Fibrinolysis. 1993;4(4):615-625.
20. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10(5):267-274.
21. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97(12): 1195-1206.
22. Briasoulis A, Tousoulis D, Antoniades C, Stefanadis C, Papageorgiou N. The role of endothelial progenitor cells in vascular repair after arterial injury and atherosclerotic plaque development. Cardiovasc Ther. April 7, 2010. [Epub ahead of print].
23. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med. 2008;86(6):663-671.
24. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol. 2001;87(8 A):25C-32C.
25. RUIZ-Ortega M, Ruperez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006;21(1):16-20.
26. Matsumoto K, Morishita R, Tomita N, et al. Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats. Heart Vessels. 2003;18(1):18-25.
27. da Cunha V, Martin-McNulty B, Vincelette J, et al. Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis. J Vasc Surg. 2006;44(2): 364-371.
28. David S, Kumpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens. 2009;27(8):1641-1647.
29. Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich). 2006;8(8 Suppl 2):31-38; quiz 40.
30. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology. 2006;13(3):129-142.
31. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97(22): 2222-2229.
32. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003;17(4):223-230.
33. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004;122(4): 339-352.
34. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol. 1997;79(5A): 3-8.
35. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22-27.
36. Mizuno Y, Jacob RF, Mason RP. Advances in pharmacologic modulation of nitric oxide in hypertension. Curr Cardiol Rep. 2010; 12(6):472-480.
37. Ferrario CM, Strawn WB. Targeting the RAAS for the treatment of atherosclerosis. Drug Discov Today Ther Strateg. 2005;2(3):221-229.
38. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag. 2007;3(6):937-945.
39. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008;21 (10):1076-1085.
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
41. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-1510.
42. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225.
43. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-925.
44. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86(5):494-501.
45. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25(5):1034-1041.
46. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23(3):551-556.
47. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999;31(1): 275-281.
48. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208-1219.
49. Perrone-Filardi P, Corrado L, Brevetti G, et al. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich). 2009;11(5):260-265.
50. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol. 2004;93(11):1432-1435, A1410.
51. Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2005;23(2):435-444.
52. Baguet JP, Asmar R, Valensi P, Nisse-Durgeat S, Mallion JM. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Vasc Health Risk Manag. 2009;5(1): 175-183.
53. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis. 2009;202(1):76-83.
54. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of longterm irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci. 2003;60(4): 191-196.
55. von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001;19(10):1813-1818.
56. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens. 2000;13(7):783-788.
57. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005;111(3): 343-348.
58. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation. 2005;111(19):2518-2524.
59. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag. 2008;4(1):89-101.
60. Gomez-Garre D, Martin-Ventura JL, Granados R, et al. Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. Kidney Int. 2006;69(7): 1237-1244.
61. Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002;72(3):302-307.
62. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007;25(4): 785-791.
63. Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J. 2008;49(1): 95-103.
64. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003; 88(9):4496-4501.
65. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol. 2005;46(6):735-739.
66. Link A, Lenz M, Legner D, Bohm M, Nickenig G. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens. 2006;24(9):1891-1898.
67. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther. 2004;26(Suppl A):A28-A32.
68. Neutel JM, Kereiakes DJ. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs. 2010;10(5):289-303.
69. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich). 2010;12(1):3-13.
70. Kyotani Y, Zhao J, Tomita S, et al. Olmesartan inhibits angiotensin II-induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways. J Pharmacol Sci. 2010;113 (2): 161-168.
71. Shimada K, Murayama T, Yokode M, Kita T, Fujita M, Kishimoto C. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Nutr Metab Cardiovasc Dis. April 14, 2010. [Epub ahead of print].
72. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 2005;23(10): 1879-1886.
73. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55(10): 976-982.
74. Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin IIreceptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;1(2): 97-106.
75. Smith RD, Yokoyama H, Averill DB, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (the VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006;6(5):335-342.
76. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103-1107.
77. Smith RD, Yokoyama H, Averill DB, Schiffrin EL, Ferrario CM. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertens. 2008;2(3): 165-172.